Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002322
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients
Sponsor:
Pharmacia and Upjohn
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Randomized Double-Blind Placebo-Controlled Comparative Dose-Response Study of Two Doses of Atevirdine Mesylate U-87201E in Combination With Fixed Doses of Zidovudine AZT in HIV Patients
Status:
COMPLETED
Status Verified Date:
1996-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the tolerance and antiviral response of two different doses of atevirdine mesylate U-87201E in symptomatic HIV-positive patients with CD4 counts of 50-350 cellsmm3 who also take zidovudine AZT
Detailed Description:
Patients are randomized to 1 of 3 treatment groups U-87201E at 1 of 2 doses or placebo administered every 8 hours Patients must have taken AZT for at least 3 months prior to randomization
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| M33300018 | None | None | None |